Prediction of Bleeding Patterns in Women After Insertion of an Intrauterine Active-Ingredient-Releasing System
Bayer, located in Germany, is developing systems for predicting the menstrual bleeding pattern using an intrauterine active-ingredient-releasing system.
Orion and Bayer will present research on their jointly developed investigational compound darolutamide for prostate cancer at the 2019 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium.
Related Posts
Cala Health Claims to Have the only Patented Neurostimulation for Essential Tremor Treatment. The Patent Data Disagrees
Cala Health has figured out that innovations backed by patents make them exponentially more valuable in the marketplace. However, in a zest…
Capital One is Investing in AI Biotech? What’s in their wallet?
In the past 18 months, Capital One has expanded past its usual banking activities, and begun exploring the AI Biotech Sector. But do they…
Google AI Reinvents Speech Recognition. Who will follow?
There is no doubt that the big 5 tech companies (Apple, Amazon, Google, Facebook, and Microsoft) have developed massive IP portfolios in…